Abstract:<section class="article-section__content"><h3 class="article-section__sub-title section1"> Introduction</h3><p>In 2017, all people with severe haemophilia B (PWSHB) in Ireland switched from standard half‐life (SHL) recombinant FIX (rFIX) to rFIX Fc fusion protein (rFIXFc) prophylaxis.</p></section><section class="article-section__content"><h3 class="article-section__sub-title section1"> Aims</h3><p>To evaluate prophylaxis regimens, bleeding rates and factor usage for two years of rFIXFc prophylaxis in a real‐world setting.</p></section><section class="article-section__content"><h3 class="article-section__sub-title section1"> Methods</h3><p>Data collected retrospectively from electronic diaries and medical records of PWSHB for a two‐year period on rFIXFc prophylaxis were compared with paired baseline data on SHL rFIX treatment.</p></section><section class="article-section__content"><h3 class="article-section__sub-title section1"> Results</h3><p>28 PWSHB (≥18 years) were enrolled, and at switchover 79% were receiving prophylaxis and 21% episodic treatment with SHL rFIX. At 24 months following switchover, all remained on rFIXFc prophylaxis with reduced infusion frequency; median dose per infusion once weekly (55 IU/kg, 20/28), every 10 days (63 IU/kg, 2/28) or every 14 days (98 IU/kg, 6/28). Median annualised bleed rate improved significantly on rFIXFc prophylaxis (2.0 versus 3.3 on SHL FIX) (<i>p </i>= 0.01). Median FIX trough level with once‐weekly infusions was 0.09 IU/ml (0.06–0.14 IU/ml). Management of bleeding episodes was similar with rFIXFc and SHL rFIX; one infusion was sufficient to treat 74% and 77% of bleeds, respectively, with similar total median treatment per bleeding episode. Factor consumption reduced by 28% with rFIXFc prophylaxis (57 IU/kg/week, range 40–86 IU/kg/week) compared with SHL rFIX (79 IU/kg/week, range 44–210 IU/kg/week) (<i>p </i>= 0.002). </p></section><section class="article-section__content"><h3 class="article-section__sub-title section1"> Conclusion</h3><p>This study provides important insights into real‐world experience of switching to rFIXFc prophylaxis in an adult population, demonstrating high rates of prophylaxis, with reduced infusion frequency, bleeding and FIX consumption.</p></section>

Long-term Clinical Outcomes of Prophylaxis With a rFVIIIFc or rFIXFc in Adults 50+ Years of Age With Hemophilia A or B

Long‐term safety and efficacy of recombinant factor VIII Fc fusion protein (rFVIIIFc) in subjects with haemophilia A

Recombinant factor VIII Fc fusion protein for the treatment of severe haemophilia A: Final results from the ASPIRE extension study

A Single-Center Retrospective–Prospective Study

Long-term safety and efficacy of rIX-FP prophylaxis with extended dosing intervals up to 21 days in adults/adolescents with hemophilia B

Superior Prophylactic Effectiveness of a Recombinant FVIIIFc Over Standard Half‐Life FVIII in Hemophilia A: A‐SURE Study

Real‐world outcomes with recombinant factor IX Fc fusion protein (rFIXFc) prophylaxis: Longitudinal follow‐up in a national adult cohort

Prophylaxis for Hemophilia in the Era of Extended Half-Life Factor VIII/Factor IX Products

Changes in Quality of Life, Adherence, and Kinesiophobia in Patients with Hemophilia Treated with Extended Half-Life Treatment: Final Results of the LongHest Project

Long-term efficacy and safety of damoctocog alfa pegol prophylaxis in patients with haemophilia A aged 12–<18 years at enrolment into PROTECT VIII

P1670: LONG TERM SAFETY AND EFFICACY OF RECOMBINANT HUMAN COAGULATION FACTOR VIII (SCT800) IN PREVIOUSLY TREATED PATIENTS WITH SEVERE HEMOPHILIA A

Factor Replacement Treatment for Hemophilia A: Achievements and Perspectives

Pharmacokinetics of Efmoroctocog alfa by Two-Compartment Model Highlights Hemophilia A Patients with Biphasic Decay, Long Mean Residence Time, and Beta Half-Life

Recombinant factor IX Fc for the treatment of hemophilia B

The effectiveness and safety of octocog alfa in patients with hemophilia A: up to 7-year follow-up of the real-world AHEAD international study

A post hoc analysis of PROTECT VIII kids assessing long‐term efficacy and safety of damoctocog alfa pegol in adolescents with severe haemophilia A

Defining extended half-life rFVIII-A critical review of the evidence

Decreased Bleeding Rates in Patients with Hemophilia A Switching from Standard-Half-Life FVIII to BAY 94-9027 Prophylaxis

Clinical outcomes of low‐dose pharmacokinetic‐guided extended half‐life versus low‐dose standard half‐life factor VIII concentrate prophylaxis in haemophilia A patients

Evaluating the Effectiveness of Prophylactic Strategies for Hemophilia A Management: A Real-World, Longitudinal Observational Study

Prophylaxis with recombinant factor IX Fc fusion protein reduces the risk of bleeding and delays time to first spontaneous bleed event in previously untreated patients with haemophilia B: A post hoc analysis of the PUPs B‐LONG study